Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

2.000 -0.040 (-1.96%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q2 Results, Corporate Update Conference Call
Via Investor Brand Network
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
From Vistagen
Via Business Wire
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Near the Top of Equities by Percentage Gain on 8/7
Via Investor Brand Network
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Inaugural Biotech CNS/Neuro Summit
Via Investor Brand Network
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Pricing of $100M Underwritten Offering
Via Investor Brand Network
Vistagen Announces Pricing of $100 Million Underwritten Offering
From Vistagen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports on Phase 2A Study Results Regarding Treatment of Premenstrual Dysphoric Disorder
Via Investor Brand Network
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), Fuji Pharma Co. Ltd. (TSE: 4554) Announce Exclusive Negotiation Agreement
Via Investor Brand Network
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Highly Accomplished Finance Professional as CFO
Via Investor Brand Network
Topics Retirement
Vistagen Appoints Cindy Anderson as Chief Financial Officer
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2024 Financial Report, Corporate Update
Via Investor Brand Network
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2024 Numbers, Corporate Update Conference Call
Via Investor Brand Network
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Fasedienol Demonstrates Potential to Transform Treatment Landscape for Social Anxiety Disorder
Via Investor Brand Network
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces New Preclinical Data Further Demonstrating Unique Mechanism of Action for Itruvone (‘PH10’)
Via Investor Brand Network
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Receipt from CIPO of Notice of Allowance for Dyskinesia Treatment
Via Investor Brand Network
Topics Intellectual Property
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2023 Financial Report, Corporate Update
Via Investor Brand Network
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
From Vistagen
Via Business Wire
InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Scheduled Conference Call to Report on FY 2023 Financial Numbers
Via Investor Brand Network
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Compliance with Nasdaq Listing Requirements
Via Investor Brand Network
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
From Vistagen
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback